Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Even slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips from wearing out, ...

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their employers. Weight-loss drugs are increasingly popular among employees ...

Weight-loss drugs are increasingly popular among employees but weigh heavily on health-insurance budgets. Popular weight-loss drugs such as Ozempic, Wegovy and Zepbound are a growing factor in ...

Rob and Julia Campbell/Stocksy Aging and limited physical activity, as well as the use of novel weight loss drugs such as Wegovy and Zepbound, often lead to the simultaneous loss of muscle mass ...

The latest weight-loss drugs including Ozempic, Wegovy, Mounjaro, and Zepbound have list prices ranging from $900 to $1,500 for a one-month supply. David Ricks, the CEO of Mounjaro and Zepbound ...